
10/5/2026
Gate Bioscience Expands Its Lilly Deal to More Than $870 Million, Adding a New Drug Target
Gate Bioscience, a privately held drug discovery company, announced Monday that it has expanded its research and licensing agreement with Eli Lilly (NYSE: LLY) in a deal now potentially worth more than $870 million. The original agreement, announced in July 2025, was worth up to $856 million. The expansion adds one drug target, with an option to add a second.
0
3 min read